Cytokinetics (CYTK) PT Raised to $82 at RBC Capital Following Bayer Partnership
Tweet Send to a Friend
RBC Capital analyst Leonid Timashev raised the price target on Cytokinetics (NASDAQ: CYTK) to $82.00 (from $80.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
